WVE Wave Life Sciences Ltd

$WVE Sept. 10 call was strategically constructive, even without new clinical data. The key near-term catalyst is FDA’s written feedback on the WVE-006 Phase 3 strategy. Wave is proposing one integrated registrational trial, with an interim analysis potentially supporting accelerated approval while the same study continues toward full approval. Written FDA feedback or meeting minutes are generally provided within approximately 30 days, depending on the meeting format. Favorable alignment could shorten development timelines, reduce capital requirements and reposition WVE-006 as a registrational-stage asset. Its RNA-editing approach could address both the lung and liver manifestations of AATD, with monthly or potentially less-frequent dosing. The market opportunity is substantial. An estimated 30,000–60,000 initially addressable severe, diagnosed patients could represent approximately $4.5B–$15B annually at orphan-disease pricing. Just 5,000 patients treated at $200,000 per year would generate approximately $1B in annual revenue. WVE-007 remains the much larger upside option. Its approximately 160-patient Phase 2a trial targets patients with BMI 35–50 and measures weight, visceral and liver fat, waist circumference, lean mass, HbA1c, lipids and insulin sensitivity. Importantly, management indicated that the WVE-007 GLP-1 combination study is imminent—and this strategy has already been partially de-risked by Arrowhead’s recently published ARO-INHBE data. ARO-INHBE plus tirzepatide produced 9.4% weight loss at 16 weeks versus 4.8% with tirzepatide alone, along with approximately 23% visceral-fat reduction. Although these are not head-to-head data and do not eliminate Wave-specific clinical risk, they provide meaningful human validation that INHBE silencing can enhance incretin-driven weight loss while potentially improving body composition. This strengthens the rationale for combining WVE-007 with a GLP-1 and could make the program strategically attractive to a major obesity company. No transaction has been announced, but positive combination data could support a partnership involving WVE-007, while favorable FDA alignment could separately increase the strategic value of WVE-006. WVE-007 could ultimately address: • Obesity monotherapy • Combination therapy for millions of GLP-1 patients • Post-GLP-1 maintenance with potentially one or two injections annually Management cited approximately 30M Americans with sarcopenic obesity. At only 1% penetration and $4,000–$8,000 annual pricing, that segment could represent approximately $1.2B–$2.4B in revenue; 5% penetration implies $6B–$12B. The post-GLP-1 maintenance opportunity could be even larger. Bottom line: WVE-006 is the nearer-term foundation with multibillion-dollar AATD potential. WVE-007 is the potentially transformative obesity asset, and Arrowhead’s data have partially de-risked the biological and commercial rationale for Wave’s imminent GLP-1 combination study.

$WVE Sept and Oct are not good for bios. Many have been down 20, 30 or 40%. Nothing has changed, same for WVE, or it has been positive since FDA allows the use of biomarkers. Considering cash and the pipeline, sp will make a turn. Hold on tight until >10

$WVE What’s going on with this one??? Figured $5 was the floor and it keeps trickling down 🤦‍♂️ Can’t be long for WVE-006 FDA written feedback 🤞

$WVE Fresh aggressive PT at $42🚀 Yesterday shorts took advantage of XBI sell-off with 56% short but the clock is ticking💥 they will get burned🔥

$WVE Wave Life Sciences got FDA alignment on the registrational pathway for WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency (company release, Oct 1). The structure is the story: a single two-year registrational trial, with a one-year interim analysis that could support accelerated approval based on AATD biomarkers. No separate confirmatory trial. Why that matters: today's standard of care is IV augmentation therapy, which can leave patients with depleted AAT levels during lung exacerbations and does nothing for the liver risk. WVE-006 is a subcutaneous RNA edit designed to produce healthy M-AAT while reducing the mutant Z-AAT aggregates trapped in the liver. Next hard read: data from the 600 mg monthly multidose cohort of the RestorAATion-2 trial, expected in Q4. The tape barely noticed. Up about 5% Thursday on the news, half of it given back Friday. Closed at 3.78, around 82% below the 52-week high.

$WVE Smart money loading at 52 wk low every day! FDA feedback on WVE006 within 30 days💎 🚀

$WVE still feel it's trading low. It should be 15$ and above after 2 good news GSK partnership going strong and FDA giving approval to fast track WVE 006

$WVE The market cap path from $765M ($3.9) to $3B+ (+$15) 💥🚀 Beam is valued $2.5B near at 52 wk low, and Viking is valued $3.88B also near 52 week low! So WVE target is $3B by EOY 💎🙌🏼

$WVE This stock reminds of VTYX. Owned a 20K stake at around $2 per share. Large institutional ownership and Sanofi had an equity stake. Stock was viciously attacked almost everyday by shorts all the way down to a dollar. Sold out at 1.50 and took the loss when no insiders bought at that ridiculous price. Stock finally bottomed and began a slow rise at first then found its legs. I did not rebuy even when it bottomed out,but should have. It was eventually bought by Lilly for $14 a share. Lesson learned that in these small bios where news is often sparse between trial news,the shorts take advantage of this and anyone owning it takes the mental abuse of the constant downward trend till they can no longer stand it and sell out. Been there and know that pain.

$WVE And i thought I naild the low at 5.02 after the 07 update, HA! Especially afte RA came out and said it was way overdone. Well, RA, what you got to say now?

$WVE if 006 gets accelerated it would be a nice anchor in the portfolio, representing a relatively high likelihood of approval within 2 years and resulting sales of at least 1 B annually, while 007 with a longer timeline and less certainly has a truly massive TAM and therefore sales potential. Seems at that point it would be a bargain for a 4-5 B takeover? With 006 the buyer can be pretty confident they’ll at least make their money back fairly soon, while 007 could make them rich. Critically WVE took back full commerce rights to 006 from $GSK in Feb which made this dynamic possible. Maybe this is the last hurdle? Or am I missing something?

$WVE To whomever it is I said to sell it all and wait to get back in after the stock popped up to $16, I just bought back in. Just FYI.

$WVE SUPER Bullish..Here is why. To answer why is stock initially down..HIGHER interests daily is poison for ALL small stocks w/o earnings..and spared very few (usually they are selling ETFs and not really picking on any single stocks), BUT after the current news involving Glaxo and then FDA news today, I am extemely bullish. Any other time it would be up to $7-9 easy. I hate analysts, but even they have recently brought down 12 month target down to over $18..I helped start Amgen years ago, and feel that is is now a very low risk/high return stock. DR Kalerman

$WVE You’re killing me smalls! Yahoo Finance was right, flush below $4 before the turnaround

$WVE It’s devastating. Hope this gives us some green eventually. Chart is total sh*t. The real issue is how it crushes your confidence. Reminds me of holding SMMT at 1.8—kept buying every dip because insider buying made me conviction-heavy. But WVE is just a straight falling knife... Anyway, sorry for the rant.

$WVE high conviction is adding when the price action stays broken for months. When the broader market keeps making fresh highs and your top position just grinds lower week after week, that extended price action causes serious self doubt. It makes you question your judgment, your thesis, and your patience. It is easy to feel confident when the chart validates you. It is a completely different discipline to stay grounded when a stock acts like it is heading for liquidation while the fundamental story remains intact. Earlier in my career, prolonged price suppression would get inside my head and force unforced errors. Over time, you learn that the market isn't here to give you daily validation. The best asymmetric setups usually feel terrible right up until they don't. True conviction means looking past extended noise, and letting the process play out without needing the chart to tell you you're right every morning, especially in small cap biotech

$WVE Macro headwinds and rapidly rising interest rates are crushing small-cap biotech. Still long; however, feeling like frogger!

$WVE down 28% in the last month I guess the only question now is how much will we be down monday - shorts appear to be making a killing right now.

$WVE My portfolio is down so much that I'm officially immune to the pain. Send it lower, I feel nothing 🚀📉😴

$WVE the sun is shining, politicians are looting the country, and wave is down at least another %. Some things never change